Mangoceuticals Engaged by Social Media Sensation Adam22 as Exclusive New Sponsor of Hit Podcasts with Skyrocketing Male Engagement
Dallas, Texas, July 18, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug branded “Mango,” is excited to announce that it has been engaged as an exclusive new sponsor by Adam22 and will be featured on a series of No Jumper and Plug Talk episodes beginning in August 2023 (https://www.youtube.com/@NoJumper).
“Adam22 has his finger on the pulse of a demographic that represents an excellent fit for MangoRx, providing a new road to achieving our revenue growth targets by reaching large audiences and promoting our products nationwide,” stated MGRX Co-Founder and CEO, Jacob Cohen. “Our focus right now is on driving powerful sales growth. This partnership holds the potential to create an enormous bump in brand awareness, sales, and market share in the growing men’s health and wellness marketplace, and we look forward to working with Adam and his team beginning next month.”
Both the No Jumper and Plug Talk podcasts have grown to amass large engaged audiences. The No Jumper social media universe has amassed nearly 12 million followers across YouTube, Instagram, Tik Tok, Twitter, and Snapchat. Nearly
Moreover, each No Jumper podcast episode averages 100-150k views/downloads, with the No Jumper channel receiving approximately 20 million monthly views. Plug Talk is new, but growing extremely fast, with 30 thousand new subscribers per month and over 50 thousand views per episode.
“We welcome MangoRx on board with open arms,” stated Josh Manheim, Chief Operating Officer of No Jumper. “We look forward to working with Jacob and his team, and we really believe this is a situation where everyone’s interests are very well aligned toward a mutually beneficial outcome. MangoRx is a disruptive new face in its marketplace, and they are once again proving that identity with this partnership.”
The Company plans on sponsoring at least 8 episodes of No Jumper and 2 episodes of Plug Talk during August and September, with more brand involvement potentially in the works. Promotional spots will feature the show’s hosts speaking organically about MangoRx and its products for at least a full minute.
Cohen continued, “Past No Jumper episodes have reached into the tens of millions of views, reaching a huge audience that is extremely well-aligned with our target market demographic. The show’s most recent episode hit 10 thousand views within two hours of being posted. This is a cultural phenomenon with enormous traction. Our promotional spots should be highly impactful, with at least a full minute of organic airtime devoted to MangoRx and our products and vision. We couldn’t be more excited about the opportunity this represents.”
About Mango
Created using a special formulation featuring the same active ingredient as in Cialis™ (Tadalafil), each part of the Mango formulation plays a critical role in helping men achieve optimum performance. We believe the key to our success lies in our unique blend of ingredients, which are used in U.S. Food and Drug Administration (“FDA”) approved drugs. Mango contains a combination of Tadalafil, Oxytocin, and L-Arginine that have been traditionally used to treat sexual dysfunction.
Mango is a prescription medication that must be approved by a physician. After an individual has completed an online tele-health visit, our network of medical providers will review and approve a prescription if medically appropriate. Mango is a rapidly dissolved tablet (RDT) that is absorbed orally. For best results, we advise taking Mango at least 15 minutes before engaging in sexual activity. Tadalafil, one of the main ingredients in Mango, typically has effects that last up to 36 hours.
About Mangoceuticals
Mangoceuticals, Inc. is a company focused on developing, marketing, and selling a variety of men's health and wellness products and services via a secure telemedicine platform. To date, the Company has identified men's wellness telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED). The Company has developed a new brand of ED product under the brand name "Mango" (think: "Man, Go!").
For more information, please visit www.MangoRx.com.
Cautionary Note Regarding Forward-Looking Statements
Certain statements made in this press release contain forward-looking information within the meaning of applicable securities laws, including within the meaning of the Private Securities Litigation Reform Act of 1995 ("forward-looking statements"). These forward-looking statements represent the Company's current expectations or beliefs concerning future events and can generally be identified using statements that include words such as "estimate," "expects," "project," "believe," "anticipate," "intend," "plan," "foresee," "forecast," "likely," "will," "target" or similar words or phrases. These forward-looking statements are subject to risks, uncertainties and other factors, many of which are outside of the Company's control which could cause actual results to differ materially from the results expressed or implied in the forward-looking statements, including, but not limited to; our ability to obtain additional funding and generate revenues to support our operations; risks associated with our ED product which have not been, and will not be, approved by the U.S. Food and Drug Administration ("FDA") and have not had the benefit of the FDA's clinical trial protocol which seeks to prevent the possibility of serious patient injury and death; risks that the FDA may determine that the compounding of our planned products does not fall within the exemption from the Federal Food, Drug, and Cosmetic Act ("FFDCA Act") provided by Section 503A; risks associated with related party relationships and agreements; the effect of data security breaches, malicious code and/or hackers; competition and our ability to create a well-known brand name; changes in consumer tastes and preferences; material changes and/or terminations of our relationships with key parties; significant product returns from customers, product liability, recalls and litigation associated with tainted products or products found to cause health issues; our ability to innovate, expand our offerings and compete against competitors which may have greater resources; our significant reliance on related party transactions; the projected size of the potential market for our technologies and products; risks related to the fact that our Chairman and Chief Executive Officer, Jacob D. Cohen, has majority voting control over the Company; risks related to the significant number of shares in the public float, our share volume, the effect of sales of a significant number of shares in the marketplace, and the fact that the majority of our shareholders paid less for their shares than the public offering price of our common stock in our recent initial public offering; the fact that we have a significant number of outstanding warrants to purchase shares of common stock at
More information on potential factors that could affect the Company's financial results is included from time to time in the "Cautionary Note Regarding Forward-Looking Statements," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's filings with the SEC, including the Company’s Quarterly Report on Form 10-Q for the Quarter ended March 31, 2023. These filings are available at www.sec.gov and at our website at https://investors.mangorx.com/sec-filings. All subsequent written and oral forward-looking statements attributable to the Company or any person acting on behalf of the Company are expressly qualified in their entirety by the cautionary statements referenced above. Other unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and takes no obligation to update or correct information prepared by third parties that are not paid for by the Company. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.
Follow Mangoceuticals and MangoRx on social media:
https://www.instagram.com/mango.rx
https://twitter.com/Mangoceuticals
https://www.facebook.com/MangoRxOfficial
Or just click here to see why Orange is the new Blue:
https://www.mangorx.com
FOR INVESTOR RELATIONS
Fraxton Market Initiatives, LLC.
Email: investors@mangorx.com
MEDIA CONTACT
PHOENIX MGMT Marketing & Consulting
info@phoenix-mediamarketing.com
SOURCE: Mangoceuticals Inc.
